Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

ndtv.com - Indo Asian News Service - New Norms For Pharma Marketing Stipulate Strict Ethical Practices: Govt
New Norms For Pharma Marketing Stipulate Strict Ethical Practices: Govt
NDTV

The government's new Uniform Code for Pharmaceutical Marketing Practices provides for setting up an Ethics Committees for Pharmaceutical Marketing Practices and appointment of Ethics Officers by pharmaceutical companies, a structured complaint…

observer.com - Sissi Cao - Walid Mehanna on Carrying the World's Oldest Pharma Giant Into the A.I. Era
Walid Mehanna on Carrying the World's Oldest Pharma Giant Into the A.I. Era
Observer

When ChatGPT set off a global corporate scramble in late 2022, Walid Mehanna was already deep into rebuilding the digital backbone at the world's oldest pharmaceutical company. As group data officer at Germany's Merck KGaA (also known as Merck…

fortune.com - Craig Garthwaite - Big pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it
Big pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it
Fortune

Patrick Swayze, Alex Trebek, and Ruth Bader Ginsburg all died of pancreatic cancer. They were wealthy enough to afford any treatment that existed. But there simply wasn't a drug available — at any price — that could save their lives.

cnbc.com - Priyanka Salve - U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
CNBC

U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing of generic drugs in India leads to a significant…

channelnewsasia.com - Rebecca Bundhun - India's pharma sector braces for impact of proposed Trump tariffs on generic drugs
India's pharma sector braces for impact of proposed Trump tariffs on generic drugs
CNA

MUMBAI: India's pharmaceutical industry is scrambling to assess the impact of proposed tariffs on generic drugs announced by United States President Donald Trump. Analysts warn the measures could disrupt global drug supply chains, push up medicine…

thehindubusinessline.com - LMW plans foray in to sectors like EVs, renewables, robotics and pharma
LMW plans foray in to sectors like EVs, renewables, robotics and pharma
BusinessLine

LMW Ltd (formerly Lakshmi Machine Works Ltd), the Coimbatore-based textile machinery, CNC machine tools, precision castings, and aerospace component manufacturer, has proposed amending the Objects Clause of its Memorandum of Association (MoA) to…

dailymail.com - Nick Rennison - How plants and poo lead to big pharma
How plants and poo lead to big pharma
Mail Online

DRUGS by Rod Flower (Yale University Press £20, 336pp) Skara Brae, a Neolithic village in Orkney, is one of the oldest settlements in Britain. During archaeological excavations, traces of medicinal plants have been found there. As Professor…

thehindubusinessline.com - Sun Pharma gets Organon shareholders' nod for its $11.75-bn acquisition proposal
Sun Pharma gets Organon shareholders' nod for its $11.75-bn acquisition proposal
BusinessLine

Sun Pharmaceutical Industries Ltd on Friday said shareholders of Organon & Co have approved its previously announced proposal to acquire the US-based firm at an enterprise valuation of $11.75 billion. The shareholder approval marks an important…

newswire.ca - Laminar Pharma Announces 'Last Patient, Last Visit' in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
Laminar Pharma Announces 'Last Patient, Last Visit' in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
CNW

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Shares Gap Up - Still a Buy?
Spyglass Pharma (NASDAQ:SGP) Shares Gap Up - Still a Buy?
MarketBeat

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $20.88, but opened at $21.80. Spyglass Pharma shares last traded at $21.2550, with a volume of 12,107 shares.

forbes.com - Danielle Chemtob - Forbes Daily: Tesla Founders Are Making Another Bet On The EV Market
Forbes Daily: Tesla Founders Are Making Another Bet On The EV Market
Forbes

Marc Tarpenning and Martin Eberhard founded Tesla, and now they're backing the next generation of electric vehicles. The pair is funding EV startup TELO, which is bringing a truck to market that's roughly the size of a MINI Cooper. The whimsical…

marketbeat.com - Atika Capital Management LLC Acquires Shares of 35,200 BridgeBio Pharma, Inc. $BBIO
Atika Capital Management LLC Acquires Shares of 35,200 BridgeBio Pharma, Inc. $BBIO
MarketBeat

Atika Capital Management LLC bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 35,200 shares of the…

marketbeat.com - Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX
Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX
MarketBeat

Inceptionr LLC boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 287.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,557 shares of the…

marketbeat.com - NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of 'Moderate Buy' from Analysts
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of 'Moderate Buy' from Analysts
MarketBeat

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have earned an average recommendation of 'Moderate Buy' from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock…

marketbeat.com - Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASND
Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASND
MarketBeat

Bank of New York Mellon Corp reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 42.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 228,675…

Receive a Daily briefing on Pharma Industry News

Get Started